The reports of the Egyptian Medicines Authority revealed good news for patients and patients with cases of bleeding with the registration of a new product bearing the scientific name “Carboxymethylcellulose”, as the first drug to stop simple and medium bleeding resulting from accidents and surgeries by 100%.
The reports said that the drug can stop the bleeding of blood for hemophilia patients and those injured in accidents, in addition to patients who take anticoagulants or platelet inhibitors within 6 to 12 seconds of its use, and it also speeds up the clotting process, and thus it stops bleeding with a double effect until reaching the nearest hospital. Within 3 hours, which represents a final solution to bleeding in patients who suffer from clotting problems, especially patients hemophilia and surgeries.
The reports indicated that the new drug is important to stop bleeding resulting from accidents, surgeries, and hemophilia patients, and continued: It contributes to stopping the bleeding that occurs during various surgeries. veins or bleeding surfaces, and it has the approval of the American and European Food and Drug Administration.
Hossam Abdel Ghaffar, a spokesman for the Ministry of Health and Population, said that the Ministry of Health always seeks in cooperation with all parties to provide all innovative preparations and medicines that would achieve a quick and speedy recovery for patients, and continued: The issue of bleeding in various diseases is very dangerous and by providing new preparations to treat them and stop the bleeding. It solves many problems, and it is of great importance to ambulances in the face of bleeding cases resulting from various accident injuries, pointing out that the Unified Procurement Authority will study savings within its annual tenders.
Dr. Massad Suleiman, Professor of Vascular Surgery and Head of the Vascular and Cardiothoracic Surgery Unit at Mansoura University, commented that the new drug is currently being used in a number of university hospitals, the army, the police and the private sector to treat bleeding resulting from surgical interventions, accident injuries, genetic fluid diseases, or acquired.
He continued: The drug is a natural extract of cellulose that has been treated so that when it comes into contact with the blood, it turns into a gelatinous substance that stops within 6: 12 seconds, before the blood clots, and it also interacts directly with the components of the blood to stimulate clotting factors and collect platelets within 2: 5 Minutes and complete clotting, which leads to the cessation of bleeding.
He continued: The new product is characterized by not affecting wound healing, not causing immune or microbial inflammation, and its ability to have an effect on all types of bleeding, whether from arteries or veins of all sizes. The body and the most exposed to high pressure and the most receptive to blood flow are the aorta and the femoral artery.
He explained: It represents a solution for patients with hemorrhagic diseases such as hemophilia and leukemia, as well as patients who take blood thinners such as aspirin or anticoagulants, as it stops bleeding for patients with heart stents, peripheral circulatory insufficiency and recurrent clots in the peripheral veins or pulmonary artery where the treatment of liquidity can continue.
